Soligenix (Soligenix) 5-Year Yield-on-Cost % : 0.00 (As of May. 10, 2024)

View and export this data going back to 1994. Start your Free Trial

What is Soligenix 5-Year Yield-on-Cost %?

Soligenix's yield on cost for the quarter that ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Soligenix's 5-Year Yield-on-Cost % or its related term are showing as below:

SNGX's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.75
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Soligenix's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Soligenix's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Soligenix's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Soligenix's 5-Year Yield-on-Cost % falls into.

Soligenix 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Soligenix is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Soligenix (NAS:SNGX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Soligenix 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Soligenix's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix (Soligenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

0A6I:UK

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Executives

Timothy R. Cote	director	3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube	officer: CMO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber	director, officer: Chairman, CEO and President	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino	officer: Chief Financial Officer	100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini	officer: CSO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin	director	7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson	director, 10 percent owner	3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza	other: Former 10% Owner	VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144